Background The relationships of the coronavirus disease 2019 (COVID-19) vaccination with reactogenicity and the humoral immune response are important to study. The current study aimed to assess the reactogenicity and immunogenicity of the Pfizer and AstraZeneca COVID-19 vaccines among adults in Madinah, Saudi Arabia. Methods A cross-sectional study, including 365 randomly selected adult Pfizer or AstraZeneca vaccine recipients who received a homologous prime-boost vaccination between February 1 st and June 30 th , 2021. Data of height and weight were collected to assess the weight status of percipients. An evaluation of seropositivity for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies was assessed using enzyme-linked immunosorbent assay (ELISA). Results Among the participants, 69% (n = 250) reported at least one vaccine-related symptom. Pain at the injection site was the most frequently reported vaccine-related symptom. The mean total score for vaccine-related symptoms was significantly higher among participants who received the AstraZeneca vaccine, women, and participants with no previous COVID-19 infection ( p < 0.05). Spike-specific IgG antibodies were detected in 98.9% of participants after the receipt of two vaccine doses, including 99.5% of Pfizer vaccine recipients and 98.3% of AstraZeneca vaccine recipients. Significantly, higher proportions of participants in the <35-year age group developed a humoral immune response after the first vaccine dose compared with the participants in other age groups. Conclusion Participants who received the Pfizer COVID-19 vaccine reported fewer vaccine-related complications compared with those who received the AstraZeneca COVID-19 vaccine, but no serious side effects were reported in response to either vaccine. Health status and age were factors that may influence COVID-19 vaccine effectiveness for the generation of antibodies against the SARS-CoV-2 spike protein.
【저자키워드】 immunogenicity, reactogenicity, Vaccines, Saudi Arabia, Pfizer, AstraZeneca, 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Vaccine, coronavirus, COVID-19 vaccine, vaccination, immunogenicity, reactogenicity, vaccine doses, antibody, cross-sectional, Symptom, Saudi Arabia, ELISA, Spike protein, vaccine dose, Pfizer, enzyme-linked immunosorbent assay, cross-sectional study, COVID-19 infection, IgG antibodies, SARS-CoV-2 spike protein, weight, Effectiveness, Complication, Seropositivity, age, Health status, humoral immune response, women, respiratory, homologous, AstraZeneca, Height, acute respiratory syndrome, Factor, Side effect, Participants, acute respiratory syndrome coronavirus, recipients, enzyme, specific IgG antibodies, injection, participant, total score, receipt, injection site, recipient, spike-specific IgG antibodies, enzyme-linked immunosorbent, Randomly, Result, selected, collected, proportion, reported, significantly higher, groups, Spike-specific IgG antibody, the SARS-CoV-2, 【제목키워드】 COVID-19,